Benoit YOU
HCL - Centre Hospitalier Lyon Sud · Service d'Oncologie Médicale - Centre Hospitalier Lyon Sud · Hospices Civils de Lyon
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Benoit YOU as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 18:21 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT07637851 · Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian CancerARCAGY/ GINECO GROUP · not yet recruiting · Ovarian Cancer · principal investigator
- Ph3NCT06476184 · Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking SurgeryARCAGY/ GINECO GROUP · recruiting · Ovarian Cancer · principal investigator
- Ph2NCT04739202 · Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)Hospices Civils de Lyon · completed · Gastric Adenocarcinoma, Metastatic Gastric Cancer, Metastatic Adenocarcinoma · principal investigator
- N/ANCT03787056 · Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer PatientsHospices Civils de Lyon · recruiting · Cancer, Breast Cancer, Gastric Cancer · principal investigator
- Ph2NCT03135769 · Avelumab in Chemo-resistant Gestational Trophoblastic NeoplasiasHospices Civils de Lyon · completed · Gestational Trophoblastic Neoplasias (GTN) · principal investigator
- Ph1/Ph2NCT02866903 · Safety of Intraperitoneal (IP) OXAliplatin (OXA) in Association With Systemic FOLFIRI Bevacizumab Chemotherapy in Patients With Peritoneal CarcinosisHospices Civils de Lyon · unknown · Peritoneal Carcinosis · principal investigator
- Ph1/Ph2NCT02755844 · Safety and Efficacy of Metronomic Cyclophosphamide, Metformin and Olaparib in Endometrial Cancer PatientsHospices Civils de Lyon · completed · Recurrent Endometrial Cancer · principal investigator
- Ph1NCT01932177 · EVESOR: a Phase 1 Trial of Everolimus and SorafenibHospices Civils de Lyon · unknown · Metastatic or Locally Advanced Solid Tumors · study director
Grants
NIH projects from RePORTER, fetched 2026-11-11 18:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 18:21 UTC. The ranking covers the 200 most relevant of 85 PubMed records, and a shared surname and initials can bring in a namesake. All 85 on PubMed
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.N Engl J Med · 20191,662 citationsRCR 62.5
- Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study.Lancet Oncol · 2020426 citationsRCR 15.2
- 381 citationsRCR 11.1
- Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.Ann Oncol · 2023333 citationsRCR 29.6
- 231 citationsRCR 7.1
- 139 citationsRCR 7.6
- 138 citationsRCR 6.1
- A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and Gynecologic Cancers.Clin Cancer Res · 2018136 citationsRCR 4.4
- CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.Clin Cancer Res · 2020118 citationsRCR 5.4
- Avelumab in Patients With Gestational Trophoblastic Tumors With Resistance to Single-Agent Chemotherapy: Cohort A of the TROPHIMMUN Phase II Trial.J Clin Oncol · 202090 citationsRCR 3.5